Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 19208539)

1.

Acute onset of polyarthralgia and high anti-cyclic citrullinated peptide antibodies in a case of idiopathic granulomatous hypophysitis.

Babey M, Aeberli D, Vajtai I, Sahli R.

J Rheumatol. 2009 Jan;36(1):204-7. doi: 10.3899/jrheum.080408. No abstract available.

PMID:
19208539
2.

Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.

Syed RH, Gilliam BE, Moore TL.

Ann Rheum Dis. 2008 Jul;67(7):1049-51. doi: 10.1136/ard.2007.084855. No abstract available.

PMID:
18556446
3.

Anti-cyclic citrullinated peptide antibodies (CCP2) in patients with psoriatic arthritis.

Ouédraogo DD, Palazzo E, Nicaise-Roland P, Somogyi N, Grootenboer-Mignot S, Hayem G, Meyer O.

Clin Exp Rheumatol. 2007 Nov-Dec;25(6):930-1. No abstract available.

PMID:
18173933
4.

Diagnostic value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.

Mofidi M, Moghadam A.

Saudi Med J. 2008 Aug;29(8):1206-7. No abstract available.

PMID:
18690324
5.

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

6.

Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.

Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC.

J Rheumatol. 2009 Apr;36(4):712-6. doi: 10.3899/jrheum.080653. Epub 2009 Mar 13.

PMID:
19286846
7.

Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.

Kitahara K, Takagi K, Kusunoki Y, Nishio S, Nozaki T, Inomata H, Takei M, Sawada S, Kawai S.

Ann Rheum Dis. 2008 Jul;67(7):1059-60. doi: 10.1136/ard.2007.082826. No abstract available.

PMID:
18556455
8.

Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy.

Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Delgado JF, Martínez-Gómez X, Trallero-Araguás E, Rodriguez-Sanchez JL, Vilardell-Tarrés M.

Rheumatology (Oxford). 2009 Jun;48(6):676-9. doi: 10.1093/rheumatology/kep065. Epub 2009 Apr 22.

9.

Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion.

Bos WH, Nielen MM, Dijkmans BA, van Schaardenburg D.

Ann Rheum Dis. 2008 Nov;67(11):1642. doi: 10.1136/ard.2007.085456. No abstract available.

PMID:
18854513
10.

Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis.

Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW, van der Helm-van Mil AH.

Ann Rheum Dis. 2008 Aug;67(8):1194-5. doi: 10.1136/ard.2008.088070. No abstract available.

PMID:
18621971
11.

Autoantibodies to cyclic citrullinated peptide in a PMR inception cohort from The PMR Outcomes Study.

Dasgupta B, Hutchings A, Hollywood J, Nutter L.

Ann Rheum Dis. 2008 Jun;67(6):903-4. doi: 10.1136/ard.2007.081935. No abstract available.

PMID:
18474666
12.

Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor.

Bossuyt X, Coenen D, Fieuws S, Verschueren P, Westhovens R, Blanckaert N.

Ann Rheum Dis. 2009 Feb;68(2):287-9. doi: 10.1136/ard.2007.085597. No abstract available.

PMID:
19139208
13.

IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.

van Tuyl LH, Lems WF, Kerstens PJ, Voskuyl AE, Dijkmans BA, Boers M.

Ann Rheum Dis. 2009 Oct;68(10):1652-3. doi: 10.1136/ard.2008.103184. No abstract available.

PMID:
19748920
14.

The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus.

Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, Liu JP, Jiang L, Chen JP.

Lupus. 2009 Jul;18(8):713-7. doi: 10.1177/0961203309102817.

PMID:
19502267
15.

Anti-cyclic citrullinated peptide in preclinical rheumatoid arthritis. Food for thought.

Ménard HA.

J Rheumatol. 2009 Apr;36(4):663-4. doi: 10.3899/jrheum.090184. No abstract available.

PMID:
19342718
16.

Anti-cyclic citrullinated peptide antibody versus HAQ/MDHAQ: comparing apples and oranges?

Bykerk V.

J Rheumatol. 2009 Aug;36(8):1565-7. doi: 10.3899/jrheum.090673. No abstract available.

PMID:
19671806
17.

Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.

Itty S, Pulido JS, Bakri SJ, Baratz KH, Matteson EL, Hodge DO.

Trans Am Ophthalmol Soc. 2008;106:75-81; discussion 81-3.

18.

Alopecia areata associated with idiopathic primary hypophysitis.

Ajith C, Gupta S, Bhansali A, Radotra BD, Kanwar AJ, Kumar B.

Clin Exp Dermatol. 2005 May;30(3):250-2.

PMID:
15807682
19.

Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection.

Bassyouni IH, Ezzat Y, Hamdy S, Talaat RM.

Clin Chem Lab Med. 2009;47(7):842-7. doi: 10.1515/CCLM.2009.189.

PMID:
19575546
20.

The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis.

Reneses S, González-Escribano MF, Fernández-Suárez A, Pestana L, Davila B, Wichmann I, García A.

J Rheumatol. 2009 Jun;36(6):1143-9. doi: 10.3899/jrheum.081075. Epub 2009 May 1.

PMID:
19411391
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk